The EMA at 20: CHMP chair on HTA, patient involvement and dealing with uncertainty
This article was originally published in SRA
Executive Summary
Getting Europe's diverse member states together to evaluate and manage human medicines was a tall order when the European Medicines Agency was created 20 years ago. It can still seem that way today. Tomas Salmonson, the chair of the EMA's Committee for Medicinal Products for Human Use, talks to Francesca Bruce* about the challenges of reaching consensus, evaluating drugs with little data, and getting patients more closely involved.